Equibles does not estimate personal net worth.
Get an email with a short summary when Bristol Myers Squibb Co publishes a filing, an earnings call transcript or a press release.
Get BMY alertsChris Boerner has spoken on 5 earnings calls across 1 company, most recently for Bristol Myers Squibb Co on April 30, 2026. Bristol Myers Squibb Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Bristol Myers Squibb Co includes Christopher Boerner (CEO, COO and Board Member), Christopher Boerner, Ph.D. (CEO, COO and Board Member), David Elkins (CFO) and 6 others.
“We delivered a solid Q1 and continue to improve our say-to-do ratio with disciplined execution across the business as we continue to best position the company for long-term sustainable growth.”
“Our third quarter results reflect our continued focus on near-term execution and building the foundation for long-term sustainable growth. During the quarter, we saw solid demand for key products across our growth and legacy portfolios.”
“Starting on Slide 4, our second quarter results reflect continued progress against our strategy to position BMS for long-term sustainable growth. In Q2, we continued to strengthen commercial performance with uptake accelerating across a number of our marketed products.”
“I'm very pleased to be speaking to you on our earnings call for the first time as a CEO, and I'm excited about the opportunity for our company to continue to deliver transformational medicines for patients.”
“Before I dive in, on a more personal note, I want to recognize Giovanni for his tremendous impact on the organization. He is consistently focused on ensuring that we are strengthening our company while delivering for patients, and I wish him every success in his next chapter.”
Source not stated
Drug Manufacturers - General · Healthcare
